"HIV Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies reactive with HIV ANTIGENS.
| Descriptor ID |
D015483
|
| MeSH Number(s) |
D12.776.124.486.485.114.254.150.440 D12.776.124.790.651.114.254.150.440 D12.776.377.715.548.114.254.150.440
|
| Concept/Terms |
HIV Antibodies- HIV Antibodies
- Antibodies, HIV
- HIV Associated Antibodies
- Antibodies, HIV Associated
- HIV-Associated Antibodies
- Antibodies, HIV-Associated
- HTLV III Antibodies
- Antibodies, HTLV III
- HTLV III LAV Antibodies
- T-Lymphotropic Virus Type III Antibodies, Human
- HTLV-III-LAV Antibodies
- Antibodies, HTLV-III-LAV
- LAV Antibodies
- Antibodies, LAV
- Lymphadenopathy Associated Antibodies
- Antibodies, Lymphadenopathy Associated
- Lymphadenopathy-Associated Antibodies
- Antibodies, Lymphadenopathy-Associated
- T Lymphotropic Virus Type III Antibodies, Human
- AIDS Antibodies
- Antibodies, AIDS
- HTLV-III Antibodies
- Antibodies, HTLV-III
|
Below are MeSH descriptors whose meaning is more general than "HIV Antibodies".
Below are MeSH descriptors whose meaning is more specific than "HIV Antibodies".
This graph shows the total number of publications written about "HIV Antibodies" by people in this website by year, and whether "HIV Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 3 | 1 | 4 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 0 | 2 |
| 2009 | 5 | 1 | 6 |
| 2010 | 3 | 0 | 3 |
| 2011 | 6 | 0 | 6 |
| 2012 | 5 | 1 | 6 |
| 2013 | 4 | 0 | 4 |
| 2014 | 7 | 1 | 8 |
| 2015 | 13 | 2 | 15 |
| 2016 | 7 | 5 | 12 |
| 2017 | 11 | 0 | 11 |
| 2018 | 12 | 5 | 17 |
| 2019 | 8 | 7 | 15 |
| 2020 | 7 | 4 | 11 |
| 2021 | 9 | 3 | 12 |
| 2022 | 3 | 7 | 10 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 3 | 5 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Antibodies" by people in Profiles.
-
Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge. Viruses. 2025 Feb 17; 17(2).
-
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance. J Virol. 2025 Feb 25; 99(2):e0173024.
-
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses. 2024 Aug 27; 16(9).
-
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
-
Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) model. Sci Rep. 2024 06 10; 14(1):13311.
-
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar; 21(3):e1004360.
-
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proc Natl Acad Sci U S A. 2024 Jan 23; 121(4):e2308942121.
-
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun. 2023 Dec 14; 14(1):8299.
-
Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines. J Virol. 2024 Jan 23; 98(1):e0147823.
-
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLoS Pathog. 2023 06; 19(6):e1011469.